CIK: 0001791827
Total reported value
$493.8M
Reporting period: 2026-03-31 · Number of holdings: 45
Avidity Partners Management LP disclosed 45 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $493.8M and a quarterly turnover rate of 74.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Avidity Partners Management LP's disclosed holdings carry a Herfindahl concentration index of 0.174 — mathematically equivalent to about 6 equally-sized positions, well below its 45 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 2.64), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 3% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add DNTH
0.0% $89.9M
Add CATX
+88.4% $16.4M
Add ELVN
+185.1% $13.5M
Trim BSX
-47.6% -$7.2M
Trim JBIO
0.0% -$1.9M
Add ORKA
+15.1% $17.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | Stock-Other | 35.76% | +10.75% | — | |
| 2 | CGON | Cg Oncology INC | Stock-Other | 17.67% | +0.03% | -12.48% | |
| 3 | ORKA | Oruka Therapeutics INC | Stock-Other | 7.55% | +1.78% | +15.14% | |
| 4 | CATX | Perspective Therapeutics INC | Stock-Other | 5.11% | +2.56% | +88.43% | |
| 5 | JBIO | Jade Biosciences INC | Stock-Other | 3.99% | -2.24% | — | |
| 6 | ELVN | Enliven Therapeutics INC | Stock-Other | 3.18% | +2.56% | +185.10% | |
| 7 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.75% | — | +7.86% | |
| 8 | CNTX | Context Therapeutics INC | Stock-Other | 2.65% | +0.32% | -9.20% | |
| 9 | RGEN | Repligen CORP | Stock-Healthcare | 1.86% | -0.52% | +54.67% | |
| 10 | PVLA | Palvella Therapeutics INC | Stock-Other | 1.77% | +1.19% | +262.69% | |
| 11 | MDT | Medtronic plc | Stock-Healthcare | 1.75% | -1.23% | -7.06% | |
| 12 | VIR | Vir Biotechnology INC | Stock-Other | 1.72% | +1.72% | NEW | |
| 13 | AKTS | Aktis Oncology INC | Stock-Other | 1.70% | +1.70% | NEW | |
| 14 | VTLUSD | Immunic INC | Stock-Other | 1.51% | +0.79% | +42.56% | |
| 15 | DXCM | Dexcom INC | Stock-Healthcare | 1.14% | +1.14% | NEW | |
| 16 | EHC | Encompass Health CORP | Stock-Healthcare | 0.82% | — | +32.91% | |
| 17 | BSX | Boston Scientific CORP | Stock-Healthcare | 0.76% | -2.39% | -47.60% | |
| 18 | TENX | Tenax Therapeutics INC | Stock-Other | 0.70% | +0.70% | NEW | |
| 19 | GILD | Gilead Sciences INC | Stock-Healthcare | 0.56% | +0.56% | NEW | |
| 20 | PHAT | Phathom Pharmaceuticals INC | Stock-Other | 0.56% | — | +21.02% | |
| 21 | KPTI | Karyopharm Therapeutics INC | Stock-Other | 0.52% | +0.23% | +244.62% | |
| 22 | CNC | Centene CORP | Stock-Healthcare | 0.46% | -0.96% | -41.37% | |
| 23 | MSLE | Satellos Bioscience INC | Stock-Other | 0.44% | +0.44% | NEW | |
| 24 | SCYXEUR | Scynexis INC | Stock-Other | 0.39% | — | — | |
| 25 | NTRA | Natera INC | Stock-Healthcare | 0.36% | -0.42% | -23.73% | |
| 26 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.36% | -1.38% | -51.66% | |
| 27 | KVUE | Kenvue INC | Stock-Consumer Staples | 0.35% | -0.81% | -57.04% | |
| 28 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 0.34% | +0.34% | NEW | |
| 29 | HIMS | Hims & Hers Health INC | Stock-Healthcare | 0.32% | +0.32% | NEW | |
| 30 | RVMD | Revolution Medicines INC | Stock-Healthcare | 0.30% | +0.30% | NEW | |
| 31 | GPCR | Structure Therapeutics INC | Stock-Other | 0.29% | +0.29% | NEW | |
| 32 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.27% | -0.55% | -45.65% | |
| 33 | CORT | Corcept Therapeutics INC | Stock-Healthcare | 0.24% | — | +36.36% | |
| 34 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 0.23% | +0.23% | NEW | |
| 35 | ABVX | Abivax Sa-adr | Stock-Other | 0.23% | +0.23% | NEW | |
| 36 | UNH | Unitedhealth Group INC | Stock-Healthcare | 0.21% | +0.21% | NEW | |
| 37 | NTLA | Intellia Therapeutics INC | Stock-Other | 0.19% | +0.19% | NEW | |
| 38 | ODD | Oddity Tech Ltd. | Stock-Other | 0.19% | +0.19% | NEW | |
| 39 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.19% | +0.19% | NEW | |
| 40 | PTON | Peloton Interactive Inc-a | Stock-Consumer Disc | 0.17% | — | — | |
| 41 | AVR | Anteris Technologies Global | Stock-Other | 0.17% | — | — | |
| 42 | ABUS | Arbutus Biopharma CORP | Stock-Other | 0.11% | — | — | |
| 43 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.08% | — | — | |
| 44 | ACAD | Acadia Pharmaceuticals INC | Stock-Healthcare | 0.06% | -0.76% | -87.87% | |
| 45 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.02% | — | — |
Performance for Q3 2026
+8.5%
Performance Last 4 Quarters
+136.9%
Based on 83% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 45 | $493.8M | 75 | |
| 2025-12-31 | 39 | $346.7M | 60 | |
| 2025-09-30 | 43 | $439.4M | 100 | |
| 2025-06-30 | 56 | $502.0M | 0 | |
| 2025-03-31 | 67 | $524.7M | 100 | |
| 2024-12-31 | 63 | $1.0B | 0 | |
| 2024-09-30 | 81 | $2.0B | 0 | |
| 2024-06-30 | 85 | $2.4B | 0 | |
| 2024-03-31 | 90 | $3.1B | 0 | |
| 2023-12-31 | 74 | $2.7B | 0 | |
| 2023-09-30 | 83 | $2.5B | 0 | |
| 2023-06-30 | 93 | $2.9B | 0 | |
| 2023-03-31 | 83 | $3.0B | 0 | |
| 2022-12-31 | 85 | $4.6B | 0 | |
| 2022-09-30 | 98 | $4.9B | 0 | |
| 2022-06-30 | 82 | $4.4B | 0 | |
| 2022-03-31 | 92 | $4.8B | 0 | |
| 2021-12-31 | 97 | $4.7B | 0 | |
| 2021-09-30 | 105 | $4.5B | 0 | |
| 2021-06-30 | 112 | $3.7B | 99 | |
| 2021-03-31 | 94 | $3.6B | 80 | |
| 2020-12-31 | 96 | $3.1B | 100 | |
| 2020-09-30 | 68 | $2.2B | 100 | |
| 2020-06-30 | 57 | $1.6B | 100 | |
| 2020-03-31 | 52 | $723.6M | 100 | |
| 2019-12-31 | 33 | $158.7M | 0 |
Avidity Partners Management LP's most significant position changes for 2026-03-31: New buy: Vir Biotechnology INC (VIR); New buy: Aktis Oncology INC (AKTS); Sold out: Alnylam Pharmaceuticals INC (ALNY); Sold out: Mckesson CORP (MCK); New buy: Dexcom INC (DXCM).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | +10.8% | — | Unchanged |
| 2 | CATX | Perspective Therapeutics INC | +2.6% | +88.43% | Add |
| 3 | ELVN | Enliven Therapeutics INC | +2.6% | +185.10% | Add |
| 4 | ORKA | Oruka Therapeutics INC | +1.8% | +15.14% | Add |
| 5 | PVLA | Palvella Therapeutics INC | +1.2% | +262.69% | Add |
| 6 | VTLUSD | Immunic INC | +0.8% | +42.56% | Add |
| 7 | CNTX | Context Therapeutics INC | +0.3% | -9.20% | Trim |
| 8 | KPTI | Karyopharm Therapeutics INC | +0.2% | +244.62% | Add |
| 9 | CGON | Cg Oncology INC | 0% | -12.48% | Trim |
| 10 | NTRA | Natera INC | -0.4% | -23.73% | Trim |
| 11 | RGEN | Repligen CORP | -0.5% | +54.67% | Add |
| 12 | GMAB | Genmab A/s -sp Adr | -0.6% | -45.65% | Trim |
| 13 | ACAD | Acadia Pharmaceuticals INC | -0.8% | -87.87% | Trim |
| 14 | KVUE | Kenvue INC | -0.8% | -57.04% | Trim |
| 15 | CNC | Centene CORP | -1% | -41.37% | Trim |
| 16 | MDT | Medtronic plc | -1.2% | -7.06% | Trim |
| 17 | ICLR | ICON Public Limited Company | -1.4% | -51.66% | Trim |
| 18 | JBIO | Jade Biosciences INC | -2.2% | — | Unchanged |
| 19 | BSX | Boston Scientific CORP | -2.4% | -47.60% | Trim |
| 20 | VIR | Vir Biotechnology INC | — | NEW | New buy |
| 21 | AKTS | Aktis Oncology INC | — | NEW | New buy |
| 22 | ALNY | Alnylam Pharmaceuticals INC | — | EXIT | Sold out |
| 23 | MCK | Mckesson CORP | — | EXIT | Sold out |
| 24 | DXCM | Dexcom INC | — | NEW | New buy |
| 25 | A | Agilent Technologies INC | — | EXIT | Sold out |
| 26 | PFE | Pfizer INC | — | EXIT | Sold out |
| 27 | DHR | Danaher CORP | — | EXIT | Sold out |
| 28 | TMO | Thermo Fisher Scientific INC | — | EXIT | Sold out |
| 29 | TENX | Tenax Therapeutics INC | — | NEW | New buy |
| 30 | NVO | Novo-nordisk A/s-spons Adr | — | EXIT | Sold out |
| 31 | CI | THE Cigna Group | — | EXIT | Sold out |
| 32 | COR | Cencora INC | — | EXIT | Sold out |
| 33 | INSM | Insmed INC | — | EXIT | Sold out |
| 34 | WAT | Waters CORP | — | EXIT | Sold out |
| 35 | GILD | Gilead Sciences INC | — | NEW | New buy |
| 36 | ACHC | Acadia Healthcare Co INC | — | EXIT | Sold out |
| 37 | ITGR | Integer Holdings CORP | — | EXIT | Sold out |
| 38 | MSLE | Satellos Bioscience INC | — | NEW | New buy |
| 39 | CRVS | Corvus Pharmaceuticals INC | — | NEW | New buy |
| 40 | HIMS | Hims & Hers Health INC | — | NEW | New buy |
| 41 | HQY | Healthequity INC | — | EXIT | Sold out |
| 42 | RVMD | Revolution Medicines INC | — | NEW | New buy |
| 43 | GPCR | Structure Therapeutics INC | — | NEW | New buy |
| 44 | TEM | Tempus Ai Inc-cl A | — | NEW | New buy |
| 45 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 46 | UNH | Unitedhealth Group INC | — | NEW | New buy |
| 47 | IQV | Iqvia Holdings INC | — | EXIT | Sold out |
| 48 | NTLA | Intellia Therapeutics INC | — | NEW | New buy |
| 49 | ODD | Oddity Tech Ltd. | — | NEW | New buy |
| 50 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-28 | Amendment | View on EDGAR |
| 2026-03-31 | 2026-05-13 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-06-17 | Amendment | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-06-17 | Amendment | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001352871
Total reported value
$493.8M
152 stks
2026-06-30
AUM within 0.0% of this institution
CIK 0001308377
Total reported value
$493.9M
158 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0000850553
Total reported value
$493.9M
235 stks
2023-09-30
Stale — no recent filing
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001802528
Total reported value
$1.4B
12 stks
2026-03-31
2 of the top 5 holdings overlap, including Dianthus Therapeutics INC
CIK 0002104501
Total reported value
$281.2M
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Oruka Therapeutics INC
CIK 0001482416
Total reported value
$697.3M
76 stks
2026-03-31
1 of the top 5 holdings overlap, including Dianthus Therapeutics INC